Date: 2011-01-31
Type of information:
phase: 3
Announcement: primary endpoint met
Company: Roche (Switzerland)
Product: Tarceva® (erlotinib)
Action mechanism: kinase inihibitor
Disease: advanced, metastatic pancreatic cancer in patients refractory to 1st line gemcitabine treatment
Therapeutic area: Cancer Oncology
Country:
Trial details:
Latest news: Roche announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim analysis it was shown that compared to platinum-based chemotherapy Tarceva® (erlotinib) significantly extended the time people with newly diagnosed advanced non small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) activating mutations lived without their disease getting worse (progression-free survival or PFS). A preliminary safety analysis showed the safety profile was consistent with previous studies of Tarceva®. Data will be submitted for presentation at a future medical meeting.
